Saturday, 31 October 2026European Markets

BALYO Stock Bullish By 27% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of BALYO (CAC 40: BALYO.PA) rose by a staggering 27.88% in 10 sessions from $0.48 to $0.61 at 13:56 EST on Monday, following the last session's downward trend. CAC 40 is sliding 1.34% to $7,137.10, after two sequential sessions in a row of gains.

BALYO's last close was $0.55, 56.5% under its 52-week high of $1.26.

About BALYO

Balyo SA designs, develops, and markets material handling robots worldwide. The company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. Its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, ERP interfacing, and palletizers; and WMS interface and 3D camera applications. The company serves 3PL, automotive, e-commerce, and consumer goods industries. Balyo SA was founded in 2004 and is headquartered in Arcueil, France.

Earnings Per Share

As for profitability, BALYO has a trailing twelve months EPS of $-0.28.

Sales Growth

BALYO's sales growth for the current quarter is negative 32.3%.

More news about BALYO (BALYO.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com